Skip to main content
Caplight Logo









REMEDI Co., Ltd.

REMEDI Co., Ltd.

Private
IncheonHealthcare & Life Scienceshttps://re-medi.co.kr/

Last Round

IPO

Jul 13, 2026

Est. Valuation

$105.27M

Total Funding Raised

$2.17M

Company Overview

REMEDI Co., Ltd. is a biotechnology company that develops peptide-based biomedical products for therapeutic and cosmetic applications using an AI-driven cell-penetrating peptide platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Fashion & Beauty

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

cell-penetrating peptidesCPPdrug delivery technologycosmeceuticalpeptide discoveryAI drug discoveryCROcontract research organizationin-silico drug designOEM/ODMbiotech R&Dskincare techbio-pharmaX-ray componentsmedical imaging

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

REMEDI Co., Ltd. Comparables

Compare REMEDI Co., Ltd. with similar companies based on industry and business-model similarity.

REMEDI Co., Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
NeoRegen Biotech
81%
ProCell Therapeutics, Inc.
76%
Icure Pharmaceutical Inc.
71%

REMEDI Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOJul 13, 2026
VC RoundApr 1, 2022
StrategicJun 1, 2020

Key People

Founding team and executive leadership

Chanho Park

CEO, Co-founder

Founding Team

REMEDI Co., Ltd. Investors

Notable investors and investment history

REMEDI Co., Ltd. investors
InvestorRounds
KB SecuritiesIPO
InterValue PartnersVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 2, 2026

    Monthly visitors increased 32% MoM.

  • Jan 25, 2025

    Monthly visitors grew 220% MoM.

REMEDI Co., Ltd. Filings

Explore SEC and related filing metadata, where available.

REMEDI Co., Ltd. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about REMEDI Co., Ltd.'s valuation, stock price, and market status.

Is REMEDI Co., Ltd. a public or private company?

REMEDI Co., Ltd. is a private company.

What is the current stock price of REMEDI Co., Ltd.?

REMEDI Co., Ltd. is a private company with no public stock price. No recent secondary market data is available.

How much is REMEDI Co., Ltd. worth (valuation)?

REMEDI Co., Ltd.'s valuation is estimated at $105.3M based on funding round data.

Can I buy REMEDI Co., Ltd. stock?

REMEDI Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was REMEDI Co., Ltd.'s last funding round?

REMEDI Co., Ltd.'s most recent funding round was IPO on July 13, 2026.

Who are the main investors in REMEDI Co., Ltd.?

Key investors in REMEDI Co., Ltd. include InterValue Partners.

Will REMEDI Co., Ltd. IPO soon?

No public IPO plans have been announced for REMEDI Co., Ltd..

How can I track REMEDI Co., Ltd. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor REMEDI Co., Ltd.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIncheon
Employee Range1
Year Founded2020
Last FundingJul 13, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?